Medtronic (MDT) Cash & Equivalents (2014 - 2026)

Medtronic has disclosed Cash & Equivalents across 13 years of filings, most recently posting $1.7 billion for Q3 2026.

• In Q3 2026, Cash & Equivalents rose 32.84% year-over-year to $1.7 billion; the TTM figure through Jul 2026 stood at $1.7 billion (up 32.84% YoY), while the FY2026 annual figure was $1.9 billion, down 12.13% from the prior year.
• Cash & Equivalents came in at $1.7 billion for Q3 2026 at Medtronic, down from $1.9 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $4.8 billion in Q4 2022 to a low of $1.1 billion in Q1 2026.
• Average Cash & Equivalents over 5 years is $2.1 billion, with a median of $1.5 billion recorded in 2023.
• Year-over-year, Cash & Equivalents tumbled 72.85% in 2023 and surged 72.74% in 2025.
• Over 5 years, Cash & Equivalents stood at $4.8 billion in 2022, then plunged by 72.85% to $1.3 billion in 2023, then increased by 6.33% to $1.4 billion in 2024, then retreated by 8.03% to $1.3 billion in 2025, then soared by 31.9% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $1.7 billion in Q3 2026, $1.9 billion in Q2 2026, and $1.1 billion in Q1 2026.